Conference Call and webcast to follow
Company Website:
http://www.auriniapharma.com
VICTORIA, British Columbia -- (Business Wire)
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced
that it will release its first quarter 2018 financial results on
Thursday, May 10, 2018, after the market closes. Aurinia’s management
will host a conference call to discuss the company’s first quarter 2018
financial results and provide a general business update.
The conference call and webcast is scheduled for May 10, 2018 at 4:30pm
EDT. In order to participate in the conference call, please dial
+1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be
accessed under "News/Events” through the “Investors” section of the
Aurinia corporate website at www.auriniapharma.com.
A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of LN, FSGS and DES. The company is headquartered in Victoria,
BC and focuses its development efforts globally. For further
information, see our website at www.auriniapharma.com.
We seek safe harbor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501006837/en/
Contacts:
Aurinia Pharmaceuticals Inc.
Investor Contact:
Celia
Economides
VP, Corporate & Public Affairs
IR@auriniapharma.com
or
Media:
Christopher
Hippolyte, 212-364-0458
Christopher.hippolyte@inventivhealth.com
Source: Aurinia Pharmaceuticals Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.